Follow the link of the selected polymorphism to read a brief description of how the selected polymorphism affects Hepatitis and see a list of existing studies.
SNP polymorphisms related to the topic Hepatitis:
|A common HLA-DPA1 variant increases the risk of chronic hepatitis B 1.8-fold.
|The rs738409 polymorphism in PNPLA3 is associated with the risk of liver damage and the development of non-alcoholic fatty liver disease. It influences the progression of fibrosis and steatosis in chronic hepatitis C.
|ITPA gene variant reduces the risk of anaemia due to anti-HCV therapy with rivarin.
|Interleukin (IL)-18 polymorphism is associated with chronic hepatitis C and B virus infections.
|HLA-DQB1 polymorphisms are associated with susceptibility to chronic hepatitis B.
|The ITPA gene variant protects against ribavirin-induced haemolytic anaemia and reduces the need for ribavirin dose reduction in hepatitis C virus treatment.
|Association of HLA-DQB1 breakage variant with susceptibility to chronic hepatitis B. Direct effect on the risk of hepatitis B virus infection in children.
|HLA-DQB2 single nucleotide polymorphism associated with hepatitis B.
|The major polymorphism rs8099917 of the IL28B gene predicts treatment outcomes in patients infected with hepatitis C virus. Associated with ineffectiveness of interferon-alpha and ribavirin therapy in chronic hepatitis C. However, at the same time, there are known cases of spontaneous cure from hepatitis C by carriers of this defect.
|IL28B genetic variability is associated with spontaneous HCV elimination, response to treatment, and blood levels of IL-28B.
|MHC locus and genetic susceptibility to persistent hepatitis B virus infection.
|The chronic hepatitis B risk allele is associated with reduced expression of HLA-DPA1 and HLA-DPB1 mRNA in normal human liver. Allows prediction of recovery from hepatitis B virus infection. Also affects both hepatitis C virus persistence and hepatitis C virus F protein formation.
|Polymorphisms influence the risk of hepatitis B virus infection.
|Polymorphism causing the risk of thrombocytopenia during pegylated interferon and ribavirin therapy for chronic hepatitis C.
|A variant of the gene encoding interferon-lambda-4 (IFN-lambda-4) predicts virus elimination induced by hepatitis C treatment. It is associated with an approximately twofold change in response to treatment with pegylated interferon-alpha (PEG-IFN-alpha) in combination with ribavirin (RBV).
|IL28B polymorphism associated with response to therapy in patients with chronic hepatitis C on the outcome of dual combination therapy for chronic hepatitis C virus infection. But also associated with spontaneous disappearance of HCV infection.